Skip to main content
. 2018 Feb 9;10:287–295. doi: 10.2147/CMAR.S155524

Figure 2.

Figure 2

Survival analysis among patients with initial bone metastasis.

Notes: (A) Patients were stratified as bone metastasis only and multiple metastasis (bone vs multiple: median survival=37 vs 21 months, P<0.001). (B) Patients were stratified as HR+/HER2− (median survival=33 months), HR+/HER2+ (median survival=41 months), HR−/HER2+ (median survival=27 months), TNBC (median survival=10 months), and unknown (median survival=18 months) (P<0.001). (C) Patients were stratified according to whether they underwent local surgery or not (surgery vs no surgery: median survival=43 vs 25 months, P<0.001).

Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor; TNBC, triple-negative breast cancer.